See more : Newlink Technology Inc. (9600.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Adial Pharmaceuticals, Inc. (ADIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adial Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hi-Tech Pipes Limited (HITECH.NS) Income Statement Analysis – Financial Results
- DLP Resources Inc. (DLPRF) Income Statement Analysis – Financial Results
- Horizons Holdings International, Corp. (HZHI) Income Statement Analysis – Financial Results
- Akkhie Prakarn Public Company Limited (AKP.BK) Income Statement Analysis – Financial Results
- Dynic Corporation (3551.T) Income Statement Analysis – Financial Results
Adial Pharmaceuticals, Inc. (ADIL)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 564.00 | 60.50K | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| Gross Profit | -564.00 | -60.50K | -55.11K | -564.00 | -565.00 | -563.00 | -565.00 | -565.00 | -565.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 4.18M | 8.40M | 5.85M | 3.97M | 368.46K | 182.11K | 146.14K | 322.11K |
| General & Administrative | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Other Expenses | 0.00 | 0.00 | 46.49K | 2.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Cost & Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Interest Income | 69.78K | 63.34K | 6.54K | 32.50K | 95.23K | 7.39K | 367.00 | 240.00 | 1.26K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.17M | 144.54K | 9.64K | 0.00 | |
| Depreciation & Amortization | 564.00 | 564.00 | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| EBITDA | -7.00M | -13.32M | -19.46M | -10.93M | -8.15M | -6.98M | -994.35K | -410.00K | -817.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.89M | -13.32M | -19.29M | -10.93M | -8.24M | -6.99M | -995.29K | -410.81K | -819.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -113.94K | 585.21K | -1.82M | 35.00K | -346.53K | -4.64M | -144.17K | -9.39K | 1.26K |
| Income Before Tax | -7.00M | -12.73M | -19.52M | -10.89M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -502.00 | -94.08K | -32.50K | -76.06K | -3.48M | 367.00 | 9.64K | 1.26K |
| Net Income | -7.00M | -12.73M | -19.42M | -10.86M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| EPS Diluted | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| Weighted Avg Shares Out | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
| Weighted Avg Shares Out (Dil) | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
CHARLOTTESVILLE, Va., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the...
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it...
Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Reported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused...
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float
Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023 Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.
Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings
CHARLOTTESVILLE, Va., July 11, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder...
Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it...
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
10 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Source: https://incomestatements.info
Category: Stock Reports